Vincent Ribrag

15PUBLICATIONS
114CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Glycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 23, 2026
Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trials.

|Mar 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Dec 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

|Sep 24, 2025
CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.

Myriam Ben Khelil, Ahmadreza Arbab, Janesa Srikanthan

|Mar 03, 2025
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Vincent Camus, Thierry Molina, Fabienne Desmots

|Nov 12, 2024
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani

Pageof 3

Frequent Collaborators

3 joint publications

Franck Morschhauser

2 joint publications

Guillaume Cartron

2 joint publications

Clémentine Sarkozy

2 joint publications

Steven Le Gouill